Increasing losses prompt Zephyrm Bioscience to seek funds through IPO
This biotech company, which focuses on the R&D of stem cell drugs, has filed for listing on the Hong Kong Stock Exchange, hoping to get a slice from the hot…
FAST NEWS: BlackRock cuts Bilibili H-share stake below 5%
The Latest: Asset manager BlackRock disclosed it sold about 2.85 million Hong Kong-listed shares of Bilibili Inc. (9626.HK, BILI.US) on Sept. 10, reducing its stake in the video site from…
FAST NEWS: Everest Medicines loss widens on drug commercialization
The Latest: Everest Medicines Ltd. (1952.HK) announced Tuesday its revenue for the first half of this year surged about 33 times to 302 million yuan ($42.3 million), while its net loss jumped 49%…
FAST NEWS: MicroPort Scientific loss narrows on market share increase
The Latest: MicroPort Scientific Corp. (0853.HK) issued a positive profit alert on Monday, forecasting a 17% increase in revenue for the first half of this year, showing a significant decrease in net loss. Looking…
FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
The latest: Asset management company BlackRock Inc. purchased 618,000 Hong Kong-listed shares of WuXi AppTec Co. Ltd. (2359.HK; 603259.SH) on March 26, raising its stake in the drug outsourcing services company from…
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
The latest: Biotech company Zai Lab Ltd. (9688.HK; ZLAB.US) reported Wednesday that its loss narrowed 24.5% to $335 million last year. Looking up: The narrower loss owed mainly to a 25% increase in revenue…
With no cure in sight, drugs firm LianBio begins exit strategy
The biotech, which obtained rights to novel drugs for use in the Chinese market, has announced a plan to wind up its business and delist from the Nasdaq just four…
Recent Articles
FAST NEWS: BlackRock cuts Bilibili H-share stake below 5%
9626.HK
BILI.US
FAST NEWS: BlackRock boosts stake in battered WuXi AppTec
2359.HK
603259.SHG
FAST NEWS: Zai Lab’s loss narrows on strengthening sales
9688.HK
ZLAB.US
RELATED ARTICLES
-
GenScript losses shrink on strong growth for cancer cell therapy
1548.HK - Health Guard plans dual listing to fund HPV vaccine fight
-
With its sale to AstraZeneca, Gracell blazes exit trail for cash-challenged Chinese biotechs
GRCL.US
-
Test results for new cancer drug take Akeso investors on wild ride
9926.HK
- CHINA BULLETIN: Factories Send Mixed Signals
- CHINA BULLETIN: Services, Trade Send Positive Signals
- CHINA BULLETIN: China Economy Off to Strong Start in 2024
